Licensing opportunity
Sentinel Oncology Ltd, a Cambridge-based company focusing on the discovery of novel cancer treatments, said its p70S6 kinase programme is now available for partnering.
The small molecule leads have been shown to inhibit p70S6 kinase at therapeutically relevant concentrations. Sentinel says this represents a significant opportunity for companies wishing to begin or to expand or activities in area.
http://www.sentineloncology.com/solutions/rnd/p70s6k/
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
